Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-05-31
2011-05-31
Singh, Anoop (Department: 1632)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S008000, C435S455000
Reexamination Certificate
active
07951532
ABSTRACT:
This invention relates to the discovery that midkine modulates pulmonary vasculature development and smooth muscle cell development. Modulation of midkine activity thus alters pulmonary vasculature development and smooth muscle cell development. The invention provides methods of modulating pulmonary disorders, smooth muscle cell related disorders, and pulmonary smooth muscle cell disorders. Disorders of particular interest include, but are not limited to, asthma and pulmonary hyperplasia. Further the invention relates to the discovery that TTF1 and HIF1 -α exhibit midkine modulating activity. The invention pertains to the discovery that midkine modulates myocardin activity.
REFERENCES:
patent: 5013720 (1991-05-01), Whitsett
patent: 5834306 (1998-11-01), Webster et al.
patent: 5837534 (1998-11-01), Olson et al.
patent: 5976873 (1999-11-01), Bohinski et al.
patent: 6015711 (2000-01-01), Olson et al.
patent: 6201165 (2001-03-01), Grant et al.
patent: 6364912 (2002-04-01), Peterson et al.
patent: 2001/0016352 (2001-08-01), Bohinski et al.
patent: 2002/0034768 (2002-03-01), Wellstein
patent: 2002/0110539 (2002-08-01), Zhu et al.
patent: 2002/0197646 (2002-12-01), Nogee et al.
patent: 2003/0053989 (2003-03-01), Kovesdi
patent: 2003/0065157 (2003-04-01), Lasek
patent: 2003/0104499 (2003-06-01), Pressman et al.
patent: 2003/0118567 (2003-06-01), Stewart
patent: 2003/0124580 (2003-07-01), Walker et al.
patent: 2003/0157065 (2003-08-01), Tagawa
patent: 2006/0099188 (2006-11-01), Tagawa
patent: 1283 255 (2003-02-01), None
patent: 1 302 539 (2003-04-01), None
patent: 04 81 0730 (2008-04-01), None
patent: PCT/US2004/037623 (2005-05-01), None
Goodman & Gilman's The Pharmacological basis of Therapeutics, McGraw-Hill, New York, NY. pp. 77-101.
Kato et al J Neuropathol Exp Neurol. 1999; 58(5):430-41.
Cheung et al Nature Genetics, 2003, 33, 422-425.
Hoshikawa et al Physiol Genomics 12: 209-219, 2003.
Garver et al Am J Respir Cell Mol Biol. 1993; 9(5):463-6.
Matsuura et al Cell Struct Funct. 2002; 27(2):109-15.
You et al BMC Med Genomics. Feb. 14, 2008;1:6.
Ishimoto J Clin Endocrinol Metab. Oct. 2006;91(10):4050-6.
Adachi Y., et al Midkine as a novel target gene for the Wilms' tumor suppressor gene (WT1). Oncogene (1996) pp. 2197-2203 (Abstract) v.13, #10.
Choudhuri R., et al. “An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis.” Cancer Res. (1997) pp. 1814-1819. (Abstract) v.57, #9.
Perl, et al. “Molecular mechanisms controlling lung morphogenesis.” Clinical Genetics (1999) p14 v.56 #1.
Paul, S. et al.. “Molecular cloning, expression, and purification of truncated midkine and its growth stimulatory activity on Wilms' tumor (G401) cells.” Cancer Lett (2001) pp. 239-244, v. 163.
Nauser, T. et al. “Diagnosis and Treatment of Pulmonary Hypertension” American Family Physician (2001) pp. 1789-1798 v.63 #9.
Yoshida Y., et al “A promoter region of midkine gene can activate transcription of exogenous suicide gene in pancreatic cancer.” Anticancer Research. (2002) pp. 117-120 v.22.
Wert, et al. “Increased expression of thyroid transcription factor-1 (TTF-1) in respiratory epithelial cells inhibits alveolization and causes pulmonary inflammation ” Developmental Biology 2002 pp. 75-87 v. 242.
Reynolds et al. J. B.C. Midkine is Regulated by Hypoxia and Causes Pulmonary Vascular Remodeling (2004) 279:37124-37132.
“Chronic Obstructive Pulmonary Disease” Data Fact Sheet U.S. Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute. NIH publication No. 03-5229. Mar. 2003.
Reynolds et al. “Thyroid Transcription Factor (TTF)-1 Regulates the Expression of Midkine (MK) During Lung Morphogenesis” Developmental Dynamics (2003) pp. 227-237 v. 227.
Tomizawa, et al “Regulatory Regions of growth-related genes can activate an exogenous gene of the alpha-fetoprotein to a comparable degree in human hepatocellular carcinoma cells” AntiCancer Research. 2003 pp. 3273-3277 v. 23, No. 4.
Yu, et al. “Cell growth- and P53-dependent transcriptional activity of the midkine promoter confers suicide gene expression in tumor cell.” Oncology Report (2003) pp. 1301-1305 v. 10.
Kaplan et al “The Growth Factor Midkine is Modulated by Both Glucocorticoid and Retinoids in Fetal Lung Development.” American Journal Respiratory Cell and Molecular Biology 2003 pp. 33-41, vol. 28.
Reynolds et al, Thyroid Transcription Factor (TTF) . . . , (Dev Dyn. 2003; 227(2): 227-237), @ 2003 Wiley-Liss, Inc. USA.
Boshoff et al. Differential Basal Synthesis of Hsp70/Hsc70 contributes to interindividual variation in Hsp70/Hsc70 inducibility, Cell Mol Life Sci, 2000 57:8 1317-25.
Gervois et al., A Truncated Human Peroxisome Proliferator Activated Receptor alpha Splice Variant with Dominant Negative Activity, Molecular Endocrinology 1999 13-9 1535-49.
Gutierrez-Rios et al, Regulatory Network ofEscherichia coli: Consistency between Literature Knowledge and Microarray Profiles, Genome Research 2003 13:2435-2443.
Adachi et al, “Midkine Promoter-based Adenoviral Vector Gene Delivery for Pediatric Solid Tumors”, Cancer Research, Aug. 15, 2000, 4305-4310, 60-16.
Durmowicz, “Mechanisms of Structural Remodeling in Chronic Pulmonary Hypertension”, Pediatrics in Review, 1999, e91-e102, v.20.
Matsubara et al, Structure of a Retinoic Acid-responsive Gene, MKn which is Transiently Activated During the Differentiation of Embryonal Carcinoma Cells and the Mid-Gestation Period of Mouse Embryogenesis, Journal of Biological Chemistry, Jun. 5, 1990, 9441-9443, 265-14.
Mucenski Michael
Whitsett Jeffrey A.
Children's Hospital Medical Center
Knobbe Martens Olson & Bear LLP
Singh Anoop
LandOfFree
Method of screening a midkine modulating agent does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of screening a midkine modulating agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of screening a midkine modulating agent will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2707397